Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB/II Study of Lorlatinib Combinations in Anaplastic Lymphoma Kinase-Rearranged Lung Cancer

NCT04292119 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04292119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04292119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB/II Study of Lorlatinib Combinations in Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 1, 2020
Completion date
March 1, 2023
Enrollment
96 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic lymphoma kinase gene translocation, lung cancer, met amplification, nsclc, relapsed cancer, resistant cancer, ros1 rearrangement